The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
The Role of Inflammation in Parkinson's Disease, 2005Development of a Dominant-Negative TNF Lentiviral Approach
Because TNF inhibitors are not believed to cross the blood-brain barrier, an orally administered TNF-based therapy is not currently possible. The Foundation has awarded supplemental funding to drive...
-
Community Fast Track, 2006The Inhibition of Neurotransmitter Release by Alpha-synuclein
Although current therapy manages the symptoms of Parkinson's disease, we still understand very little about the underlying mechanism of degeneration, and hence have no treatment that addresses the...
-
Community Fast Track, 2006D3 Receptor Selective Drugs for Parkinson's Dyskinesia
Biomedical research has defined two categories of dopamine receptors, the D1-like (D1 and D5 receptor subtypes) and D2-like (D2, D3 and D4 receptor subtypes) receptors. Despite the similarities in the...
-
Community Fast Track, 2006T Cell Mediated Neuroprotection by Therapeutic Vaccination for Parkinson's Disease
Parkinson's disease is a progressive neurodegenerative disorder whereby the neurons of the brain that control movement die. Although the events that initiate the death of those neurons remain unknown...
-
Community Fast Track, 2006AAV-Based Approach for Regulatable and Cell Type-Specific Gene Therapy in PD: Restoring Excitability to an Intrinsically Silenced Subpopulation of GP Neurons
Abnormally synchronized activity within the basal ganglia, specifically between the external globus pallidus (GPe) and subthalamic nucleus (STN), is a hallmark of altered network activity in Parkinson...
-
Community Fast Track, 2006Intravenous GDNF Gene Therapy of Experimental Parkinson's Disease
Parkinson's disease is caused by the loss of cells in the brain that produce a chemical called dopamine, which is also called a monoamine. The loss of these cells has been delayed in pre-clinical...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.